Reproterol

Abstract: Radioiodinated fenoterol and reproterol were prepared by electrophilic radioiodination reaction using chloramin-T as oxidizing agent with radiochemical yields of 97.7 ± 0.7 and 95.2 ± 0.3 %, respectively, and in vitro stability up to 72 h. Biodistribution study performed in male Albino Swiss mice showed maximum radioactivity accumulation in lungs tissue to the extent of 52 ± 1.03 and 50.6 ± 1.2 % ID/g at 15 and 30 min post injection (p.i.) for radioiodinated fenoterol and reproterol, respectively, with low accumulation in heart and blood. The clearance pathway of both iodo-compounds was through renal and hepatobiliary routes. The selectivity of iodo-compounds to lung was examined by in vivo receptor blocking study. Radioiodinated fenoterol and reproterol are not a blood products and so they are more safer than the currently available 99mTc-MAA, and their lungs uptake is higher than that of the recently discovered 125/123I-IPMPD, 99mTc(CO)5I, 99mTc-DHPM and 125/123I-paroxetine. So, radioiodinated fenoterol and reproterol could be introduced as a new compromising radiopharmaceuticals for lung perfusion scintigraphy more safe than the currently available 99mTc-MAA and more potential than the recently discovered 125/123I-IPMPD, 99mTc(CO)5I, 99mTc-DHPM and 125/123I-paroxetine.

Abstract: A new, rapid and economical flow-injection (FI) method for deter-mining some phenolic sympathomimetic drugs is proposed. These drugs are etilefrine hydrochloride (ET), fenoterol hydrobromide (FT), hexoprenaline sulphate (HP), orciprenaline sulphate (OP) and reproterol hydrochloride (R.T). The determination is based on the reaction of the studied phenolic sympathomimetic drugs with 4-aminoantipyrine (4-AAP) and potassium hexacyanoferrate (III). The chemical reaction variables and also the FI variables, were optimized on the basis of sensitivity, sampling rate and reagent consumption. The proposed technique was applied to the analysis of pure raw materials in concentrations ranging from 2-20 μg.ml−1 in case of ET, 4-30 μg.ml−1 in case of FT and OP and from 8-50 μg.ml−1 in case of HP and RT. Samples can be introduced at rates of about 130 per hour. The suggested procedure retained its accuracy and precision when applied to the analysis of pharmaceutical dosage forms containing the corresponding drug...

Abstract: β-Adrenergic bronchodilators can prevent the development of exercise-induced asthma (EIA). To investigate the duration of this effect, we determined the time at which the protective effect of salbutamol diminished significantly in six subjects. All had stable asthma known to be triggered by exercise. Following a control exercise test, identical tests were repeated weekly at various times (1–6 hours) after inhalation of 200 μg of salbutamol. Significant protection ( A further exercise test was performed after inhalation of 1 mg of reproterol, at the time when salbutamol no longer afforded significant protection. There was a significantly smaller fall in peak expiratory flow rate after exercise ( P There was no relationship between the degree or duration of protection from EIA and the bronchodilator effect of the drugs, the age and sex of the subjects, the length of asthma history or severity of base-line EIA, except perhaps the requirement for regular treatment with a steroid aerosol or sodium cromoglycate.